Erlotinib

證據等級: L5

預測適應症: 10 個

Erlotinib: From Non-Small Cell Lung Cancer to Ewing Sarcoma

One-Sentence Summary

Erlotinib (Tarceva®) is a first-generation EGFR tyrosine kinase inhibitor (TKI) approved in the US for non-small cell lung cancer (NSCLC) and pancreatic cancer, though it is not currently registered in Singapore. The TxGNN model predicts it may be effective for Ewing Sarcoma, with 1 clinical trial and 2 publications currently supporting this direction. However, the sole clinical trial was withdrawn before any patient was enrolled, and the evidence base remains at the preclinical and early exploratory stage.

Quick Overview

Item	Content
Original Indication	Non-Small Cell Lung Cancer (NSCLC); Pancreatic Cancer
Predicted New Indication	Ewing Sarcoma
TxGNN Prediction Score	95.77%
Evidence Level	L3
Singapore Market Status	✗ Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not retrievable from the DrugBank integration in this evidence pack. Based on published literature within this pack, erlotinib is a selective, reversible inhibitor of the EGFR (HER1/ErbB1) intracellular tyrosine kinase domain. By blocking EGFR autophosphorylation, it suppresses downstream RAS–MAPK and PI3K–AKT signalling cascades that drive tumour cell proliferation, survival, angiogenesis, and metastasis. Its clinical efficacy in EGFR-mutated NSCLC and pancreatic cancer is well established globally, though it is not registered in Singapore.

The mechanistic rationale for Ewing sarcoma rests on documented EGFR and HER3 (ErbB3) co-expression in Ewing sarcoma cell lines. HGF/c-MET cross-activation with EGFR has been shown to promote tumour survival in these cells. A preclinical xenograft study (Bandyopadhyay et al., 2018; PMID 29080385) directly tested the combination of the anti-HER3 antibody patritumab with erlotinib alongside standard cytotoxic agents (cisplatin, vincristine, cyclophosphamide) in paediatric sarcoma models expressing relevant ErbB receptors and ligands — providing the most direct preclinical rationale available.

While Ewing sarcoma (a primitive neuroectodermal tumour) and NSCLC differ substantially in histological origin, shared dependency on ErbB family signalling provides a biologically plausible but unproven therapeutic bridge. The TxGNN model's prediction is mechanistically coherent, but no patient-level efficacy data yet exist to support clinical translation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02689336	Phase 2	Withdrawn	0	Planned trial of erlotinib + temozolomide in relapsed/recurrent/refractory paediatric solid tumours with EGFR, ERBB2, or JAK2V617F mutations (Ewing sarcoma-eligible); withdrawn before any patient enrollment — no efficacy or safety data generated.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29080385	2018	Preclinical Study	Pediatric Blood & Cancer	Evaluated patritumab (anti-HER3) ± erlotinib combined with cisplatin, vincristine, and cyclophosphamide in paediatric sarcoma xenograft models expressing ErbB receptors; assessed dual ErbB axis inhibition strategy in the context of standard cytotoxic backbones.
26835334	2014	Review	Translational Pediatrics	Broad review of advances in paediatric cancer treatment over the past decade; contextualises the role of risk-adapted and molecularly targeted therapies in childhood solid tumours including Ewing sarcoma.

Singapore Market Information

Erlotinib is currently not registered in Singapore. No HSA marketing authorisations are on record. Physicians wishing to use erlotinib in Singapore would need to proceed via the Special Access Route (SAR) or equivalent regulatory pathway.

Cytotoxicity

Erlotinib is an anticancer agent approved for malignant indications (NSCLC, pancreatic cancer).

Item	Content
Cytotoxicity Classification	Targeted therapy — EGFR tyrosine kinase inhibitor (4-anilinoquinazoline class)
Myelosuppression Risk	Low — haematological toxicity is uncommon with EGFR TKIs; myelosuppression is not a primary concern
Emetogenicity Classification	Low
Monitoring Items	Liver function tests (ALT, AST, bilirubin), renal function, CBC, pulmonary function/chest imaging (ILD risk), skin and ophthalmological assessment
Handling Protection	Oral tablet formulation; standard cytotoxic handling precautions apply per institutional policy

Safety Considerations

No drug–drug interaction data or formal regulatory safety text is available in the current evidence pack. Please refer to the Tarceva® (erlotinib) prescribing information for complete warnings, contraindications, and interaction data.

Based on established class-effect knowledge for EGFR TKIs:

Skin toxicity: Acneiform/papulopustular rash is very common (>50% of patients) and may paradoxically correlate with therapeutic response
Interstitial Lung Disease (ILD): Rare but potentially fatal; any new or worsening pulmonary symptoms require prompt investigation and treatment discontinuation
Hepatotoxicity: Transaminase elevation observed; baseline and periodic liver function monitoring required
Gastrointestinal toxicity: Diarrhoea and stomatitis are dose-dependent and common
Ocular toxicity: Dry eye, keratitis, and corneal ulceration reported (PMID 37026321)

Conclusion and Next Steps

Decision: Hold

Rationale: The only identified clinical trial (NCT02689336) was withdrawn before enrolling a single patient, yielding no clinical efficacy or safety data for erlotinib in Ewing sarcoma. The mechanistic hypothesis — dual ErbB axis inhibition via EGFR/HER3 co-expression in Ewing sarcoma — is biologically plausible and supported by one preclinical xenograft study, but this falls short of the evidence threshold required to advance to clinical evaluation without further groundwork.

To proceed, the following is needed:

Preclinical validation: Confirm EGFR/HER3 expression levels and erlotinib sensitivity in contemporary Ewing sarcoma cell lines and patient-derived xenograft (PDX) models
Biomarker strategy: Define EGFR/ErbB pathway activation status as a patient selection criterion before any clinical trial design
Safety data gap: Obtain full erlotinib prescribing information (Tarceva® SmPC or FDA label) and complete drug interaction profile, particularly for paediatric populations
MOA data: Retrieve complete DrugBank pharmacology and pharmacokinetic profile
Regulatory pathway: Identify whether compassionate use or Special Access Route application would be required for Singapore use
Clinical opportunity: Monitor for open Phase 1/2 basket trials including paediatric EGFR-pathway-aberrant solid tumours that could accommodate Ewing sarcoma patients
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.